FY2025 EPS Estimates for Mesoblast Cut by Cantor Fitzgerald

Mesoblast Limited (NASDAQ:MESO) – Equities researchers at Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for shares of Mesoblast in a report issued on Monday, March 31st. Cantor Fitzgerald analyst K. Kluska now expects that the company will earn ($0.71) per share for the year, down from their prior forecast of ($0.70). Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Mesoblast’s current full-year earnings is ($0.70) per share.

Several other brokerages have also recently commented on MESO. Jefferies Financial Group cut shares of Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. Piper Sandler reiterated an “overweight” rating and issued a $24.00 target price (up previously from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Mesoblast Stock Down 4.6 %

NASDAQ MESO opened at $11.90 on Wednesday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. Mesoblast has a 12 month low of $4.60 and a 12 month high of $22.00. The company’s fifty day moving average price is $16.09 and its two-hundred day moving average price is $13.29.

Institutional Trading of Mesoblast

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Lindbrook Capital LLC grew its stake in Mesoblast by 70.9% during the 4th quarter. Lindbrook Capital LLC now owns 2,172 shares of the company’s stock worth $43,000 after buying an additional 901 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Mesoblast by 22.1% during the fourth quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock worth $133,000 after acquiring an additional 1,213 shares during the last quarter. R Squared Ltd acquired a new stake in shares of Mesoblast in the 4th quarter worth about $30,000. Prosperity Wealth Management Inc. boosted its stake in Mesoblast by 2.0% during the 4th quarter. Prosperity Wealth Management Inc. now owns 93,245 shares of the company’s stock valued at $1,846,000 after purchasing an additional 1,795 shares during the period. Finally, Quadrant Capital Group LLC boosted its stake in Mesoblast by 41.1% during the 4th quarter. Quadrant Capital Group LLC now owns 6,496 shares of the company’s stock valued at $129,000 after purchasing an additional 1,891 shares during the period. 1.43% of the stock is currently owned by institutional investors and hedge funds.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.